Groundbreaking research published providing benefits of light therapy on Parkinson's symptoms

Research measuring the impact of PBM on reducing Parkinson’s symptoms in a group of Adelaide-based patients was published in BMC Neurology, a leading UK science journal. Congratulations to our Chief Scientist, Dr Ann Liebert, for her stewardship in completing this trial, as well as SYMBYX Microbiologist, Dr Brian Bicknell. We have had many enquiries from people with Parkinson’s, as well as interested Carers, Neurologists, and health professionals upon publication of this research on 2 July 2021. The trial participants used the PDCare Laser by SYMBYX (made by partner company Irradia of Sweden).

Did you know? This important research was actually a catalyst for the forming of SYMBYX in 2019. Our vision is to see widespread use of PBM therapy in the treatment of diverse conditions, including Parkinson’s, Fibromyalgia and other microbiome or gut mediated indications.

The BMC manuscript concluded

“PBM was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT (Randomised Control Trial) is warranted”.